Drugs / TT-4
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04969315 | Jun 2023 → Jun 2026 overdue | castration-resistant prostate carcinoma, colorectal cancer, endometrial cancer, head and neck squamous cell carcinoma +3 | Portage Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04976660 | Dec 2022 → Jun 2023 | colorectal cancer, gastric cancer, hepatocellular carcinoma, malignant pancreatic neoplasm | Tarus Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04976660 ↗ |
| Route | Oral | “TT-4 is orally administered QD” NCT04969315 ↗ |